Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma (NCT05694871)
Official Title A Randomized Phase 2 Trial With a Safety Lead-In to Evaluate Palbociclib Versus Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial compares the effect of treatment with palbociclib alone to treatment with palbociclib plus cemiplimab for treating patients with dedifferentiated liposarcoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Palbociclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Cemiplimab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. The combination of these two drugs may be more effective in shrinking or stabilizing advanced dedifferentiated liposarcoma compared to palbociclib alone.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (194 Sites)
Showing the first 25 of 194 sites.
- University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Cancer Center at Saint Joseph's — Phoenix, Arizona
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- Mayo Clinic in Arizona — Scottsdale, Arizona
- Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- Mercy Cancer Center - Carmichael — Carmichael, California
- Mercy San Juan Medical Center — Carmichael, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- Kaiser Permanente Dublin — Dublin, California
- Mercy Cancer Center - Elk Grove — Elk Grove, California
- Kaiser Permanente-Fremont — Fremont, California
- Fresno Cancer Center — Fresno, California
- Kaiser Permanente-Fresno — Fresno, California
- Mercy Cancer Center — Merced, California
- Kaiser Permanente-Modesto — Modesto, California
- Kaiser Permanente Oakland-Broadway — Oakland, California
- Kaiser Permanente-Oakland — Oakland, California
- Kaiser Permanente-Rancho Cordova Cancer Center — Rancho Cordova, California
- Kaiser Permanente- Marshall Medical Offices — Redwood City, California
- Kaiser Permanente-Richmond — Richmond, California
- Mercy Cancer Center - Rocklin — Rocklin, California
- Rohnert Park Cancer Center — Rohnert Park, California
- Kaiser Permanente-Roseville — Roseville, California
- The Permanente Medical Group-Roseville Radiation Oncology — Roseville, California
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Dedifferentiated Liposarcoma
Explore by condition: All Advanced Dedifferentiated Liposarcoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.